Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.

Alpajaro SIR, Harris JAK, Evans CP.

Prostate Cancer Prostatic Dis. 2018 Aug 16. doi: 10.1038/s41391-018-0078-1. [Epub ahead of print]

PMID:
30115959
2.

KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.

Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, Chu CY, Hsieh CL, Sung SY, Li CF, Tepper CG, Ann DK, Gao AC, Evans CP, Izumiya Y, Chuu CP, Wang WC, Chen HW, Kung HJ.

Oncogene. 2018 Aug 2. doi: 10.1038/s41388-018-0414-x. [Epub ahead of print]

PMID:
30072740
3.

Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia-telangiectasia.

Judge SJ, Plescia TA, Bateni CP, Darrow MA, Evans CP, Canter RJ.

Rare Tumors. 2018 Jul 22;10:2036361318789724. doi: 10.1177/2036361318789724. eCollection 2018.

4.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19.

5.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ.

J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.

PMID:
29985747
6.

Intra vs Inter Cross-Resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.

Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2018 Jun 11. pii: molcanther.1269.2017. doi: 10.1158/1535-7163.MCT-17-1269. [Epub ahead of print]

PMID:
29891490
7.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM Jr.

JAMA. 2018 May 8;319(18):1880-1888. doi: 10.1001/jama.2018.4657.

PMID:
29801011
8.

Development of a stress response therapy targeting aggressive prostate cancer.

Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D.

Sci Transl Med. 2018 May 2;10(439). pii: eaar2036. doi: 10.1126/scitranslmed.aar2036.

PMID:
29720449
9.

Local treatment for metastatic prostate cancer: A systematic review.

Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP.

Int J Urol. 2018 May;25(5):390-403. doi: 10.1111/iju.13535. Epub 2018 Mar 23. Review.

PMID:
29572963
10.

A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome.

Yuh LM, Lara PN Jr, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA.

Can Urol Assoc J. 2017 Sep;11(9):E344-E349. doi: 10.5489/cuaj.4402.

11.

Bipolar androgen therapy: an intriguing paradox.

Evans CP.

Lancet Oncol. 2018 Jan;19(1):8-10. doi: 10.1016/S1470-2045(17)30907-5. Epub 2017 Dec 14. No abstract available.

PMID:
29248235
12.

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.

PMID:
29206995
13.

Genomic Markers in Prostate Cancer Decision Making.

Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.

Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10. Review.

PMID:
29129398
14.

Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP.

Urol Oncol. 2018 Feb;36(2):79.e11-79.e17. doi: 10.1016/j.urolonc.2017.10.008. Epub 2017 Nov 10.

PMID:
29129353
15.

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI.

Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. No abstract available.

PMID:
29088323
16.

Utility of Anterior Zone Biopsy in Men Enrolled in Active Surveillance for Prostate Cancer.

Glass AS, Pugashetti NB, Dall'Era MA, Evans CP, Yap SA.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30204-5. doi: 10.1016/j.clgc.2017.07.007. [Epub ahead of print]

PMID:
28789835
17.

Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium.

Rodriguez Faba O, Linares E, Tilki D, Capitanio U, Evans CP, Montorsi F, Martínez-Salamanca JI, Libertino J, Gontero P, Palou J.

Eur Urol Focus. 2017 Feb 9. pii: S2405-4569(17)30018-4. doi: 10.1016/j.euf.2017.01.009. [Epub ahead of print]

PMID:
28753848
18.

Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.

Tilki D, Schaeffer EM, Evans CP.

Eur Urol Focus. 2016 Dec;2(5):499-505. doi: 10.1016/j.euf.2016.11.013. Epub 2016 Dec 9. Review.

19.

Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.

Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ.

Eur Urol Focus. 2016 Dec;2(5):469-471. doi: 10.1016/j.euf.2016.10.011. Epub 2016 Nov 14.

PMID:
28723508
20.

ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Oct;16(10):2257-2266. doi: 10.1158/1535-7163.MCT-17-0179. Epub 2017 Jul 11.

PMID:
28698198
21.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

22.

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.

23.

MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC.

Prostate. 2017 Jun;77(9):1020-1028. doi: 10.1002/pros.23358.

24.

The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy.

Tilki D, Evans CP.

Eur Urol. 2018 Feb;73(2):176-177. doi: 10.1016/j.eururo.2017.04.020. Epub 2017 Apr 26. No abstract available.

PMID:
28456348
25.

Adjunct Screening of NKX3.1 Expression Supports 5α-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance.

Yang JC, Evans CP.

Eur Urol. 2017 Oct;72(4):507-508. doi: 10.1016/j.eururo.2017.04.019. Epub 2017 Apr 25. No abstract available.

PMID:
28454662
26.

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.

Cucchiara V, Yang JC, Mirone V, Gao AC, Rosenfeld MG, Evans CP.

Cancers (Basel). 2017 Jan 16;9(1). pii: E9. doi: 10.3390/cancers9010009. Review.

27.

TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies.

Lara PN Jr, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00065. Epub 2017 Nov 2.

28.

Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?

Chandrasekar T, Pugashetti N, Durbin-Johnson B, Dall'Era MA, Evans CP, deVere White RW, Yap SA.

Bladder Cancer. 2016 Oct 27;2(4):441-448. doi: 10.3233/BLC-160071.

29.

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Jan;16(1):35-44. doi: 10.1158/1535-7163.MCT-16-0186. Epub 2016 Oct 28.

30.

Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival.

Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R.

J Surg Oncol. 2016 Nov;114(6):764-768. doi: 10.1002/jso.24395. Epub 2016 Aug 26.

31.

Re: Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.

Tilki D, Evans CP.

Eur Urol. 2016 Dec;70(6):1079-1080. doi: 10.1016/j.eururo.2016.08.030. Epub 2016 Aug 25. No abstract available.

PMID:
27567208
32.

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B.

Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28.

33.

Autophagy and urothelial carcinoma of the bladder: A review.

Chandrasekar T, Evans CP.

Investig Clin Urol. 2016 Jun;57 Suppl 1:S89-97. doi: 10.4111/icu.2016.57.S1.S89. Epub 2016 Jun 10. Review.

34.

Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry.

Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN Jr.

World J Urol. 2017 Feb;35(2):277-283. doi: 10.1007/s00345-016-1870-y. Epub 2016 Jun 15.

PMID:
27306686
35.

Corrigendum: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW.

Nat Med. 2016 Jun 7;22(6):692. doi: 10.1038/nm0616-692b. No abstract available.

PMID:
27270780
36.

Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer.

Klotz L, Evans CP.

J Urol. 2016 Aug;196(2):309-11. doi: 10.1016/j.juro.2016.05.008. Epub 2016 May 7. No abstract available.

PMID:
27164513
37.

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW.

Nat Med. 2016 May;22(5):488-96. doi: 10.1038/nm.4070. Epub 2016 Mar 28. Erratum in: Nat Med. 2016 Jun 7;22(6):692.

38.

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX.

Cancer. 2016 Jun 15;122(12):1897-904. doi: 10.1002/cncr.29927. Epub 2016 Mar 28.

39.

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B.

Eur Urol. 2016 Oct;70(4):675-683. doi: 10.1016/j.eururo.2016.03.017. Epub 2016 Mar 19.

PMID:
27006332
40.

Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Chandrasekar T, Yang JC, Gao AC, Evans CP.

Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. Review.

41.

Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few.

Tilki D, Evans CP.

Eur Urol. 2016 May;69(5):821-2. doi: 10.1016/j.eururo.2015.12.008. Epub 2015 Dec 21. No abstract available.

PMID:
26719013
42.

Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.

Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC.

Prostate. 2016 Apr;76(5):445-55. doi: 10.1002/pros.23134. Epub 2015 Dec 30.

43.

Salvage radical prostatectomy: a few good men.

Chandrasekar T, Evans CP.

BJU Int. 2016 Jan;117(1):9-10. doi: 10.1111/bju.13172. No abstract available.

44.

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.

Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ, deVere White RW.

Cancer Res. 2015 Dec 15;75(24):5309-17. doi: 10.1158/0008-5472.CAN-14-0795. Epub 2015 Nov 16.

45.

Urethral recurrence after cystectomy: current preventative measures, diagnosis and management.

Chan Y, Fisher P, Tilki D, Evans CP.

BJU Int. 2016 Apr;117(4):563-9. doi: 10.1111/bju.13370. Epub 2015 Dec 12. Review.

46.

Targeting molecular resistance in castration-resistant prostate cancer.

Chandrasekar T, Yang JC, Gao AC, Evans CP.

BMC Med. 2015 Sep 1;13:206. doi: 10.1186/s12916-015-0457-6. Review.

47.

NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.

Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2015 Aug;14(8):1884-95. doi: 10.1158/1535-7163.MCT-14-1057. Epub 2015 Jun 8.

48.

Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.

Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC.

Prostate. 2015 Sep;75(13):1341-53. doi: 10.1002/pros.23015. Epub 2015 May 13.

49.

Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.

Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

J Urol. 2015 Aug;194(2):304-308. doi: 10.1016/j.juro.2015.02.2948. Epub 2015 Mar 19.

50.

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.

Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC.

Cancer Res. 2015 Apr 1;75(7):1413-22. doi: 10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3.

Supplemental Content

Loading ...
Support Center